论文部分内容阅读
用改进后的消炎痛VCu200（药V）与VCu200、TCu220进行随机比较性研究，共300例。在24个月末，每100妇女累积续用率分别为95．00％、82．66％、87．60％。妊娠：药V组无，VCu200有1例，TCu220有2例。脱落：药V组与TCu220各为2例，vCu200有4例。因症取出主要原因是月经过多及点滴出血分别为2例、7例、5例。月经过多的发生率，药V组显著低于对照组，在18个月内（P＜0.05），3个月内（P＜0．01）；点滴出血的发生率，药V组也显著低。因此，在结构与工艺上改进后的合消炎痛VCu200不但续用率有所提高，且能减少月经过多及点滴出血，有必要进一步多中心临床研究。
With improved indomethacin VCu200 (drug V) and VCu200, TCu220 randomized comparative study of 300 cases. At the end of 24 months, the cumulative renewal rates per 100 women were 95.00%, 82.66% and 87.60% respectively. Pregnancy: drug V group no, VCu200 in 1 case, TCu220 in 2 cases. Off: drug V group and TCu220 each for 2 cases, vCu200 in 4 cases. Symptoms removed due to menorrhagia and bleeding were 2 cases, 7 cases, 5 cases. The incidence of menorrhagia, drug V group was significantly lower than the control group, within 18 months (P <0.05), within 3 months (P <0.01); drip bleeding incidence, drug V group was also significant low. Therefore, in the structure and process improved combination of anti-inflammatory VCu200 not only increased the rate of reuse, and can reduce menorrhagia and drip, there is a need for further multicenter clinical studies.